Loading clinical trials...

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3972406 in Adults With Moderate-to-Severe Plaque Psoriasis

NCT06176768•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline
•Have venous access sufficient to allow for blood sampling
•Are able to swallow oral medication

Exclusion Criteria

•Have any other skin conditions, excluding plaque psoriasis
•Have a current or recent acute, active infection
•Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.
•Are lactating or breastfeeding women

Locations (12)

Dermatology Research Associates

Los Angeles, California, United States

Clinical Science Institute

Santa Monica, California, United States

Driven Research

Coral Gables, Florida, United States

Conquest Research

Winter Park, Florida, United States

Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey, United States

Schweiger Dermatology Group

Hackensack, New Jersey, United States

Metropolitan Dermatology - Clark

Kenilworth, New Jersey, United States

Accellacare - Winston-Salem

Winston-Salem, North Carolina, United States

Remington-Davis, Inc

Columbus, Ohio, United States

DermDox Centers for Dermatology

Camp Hill, Pennsylvania, United States

Key Dates

Start Date

December 6, 2023

Primary Completion Date

April 1, 2025

Completion Date

May 6, 2025

Last Updated

October 15, 2025

Enrollment

ACTUAL participants

Conditions

Plaque Psoriasis

Interventions

LY3972406

DRUG

Placebo

DRUG

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Plaque Psoriasis

View study

RECRUITINGPHASE2

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

NCT07449702

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Inclusion Criteria

Exclusion Criteria

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis